Development of plasmin and plasma kallikrein selective inhibitors and their effect on M1 (melanoma) and ht29 cell lines

Development of plasmin and plasma kallikrein selective inhibitors and their effect on M1 (melanoma) and ht29 cell lines Active site-directed plasmin inhibitors: Extension on the P2 residue YM-216391, a Novel Cytotoxic Cyclic Peptide from Streptomyces nobilis Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution Cytochrome P450 1 enzyme inhibition and anticancer potential of chromene amides from Amyris plumieri Inhibition of Plasminogen Activator Inhibitor-1 Activity by Two Diketopiperazines, XR330 and XR334 Produced by Streptomyces sp. 6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer Novel 20-Carbonate Linked Prodrugs of Camptothecin and 9-Aminocamptothecin Designed for Activation by Tumour-Associated Plasmin Precursor-Directed Generation of Indolocarbazoles with Topoisomerase IIα Inhibitory Activity Design and synthesis of 7-alkoxy-4-heteroarylamino-3-quinolinecarbonitriles as dual inhibitors of c-Src kinase and nitric oxide synthase